WALTHAM, Mass. & PARIS--(BUSINESS WIRE)--Echosens, a high-technology company offering the FibroScan family of products, today announces the publication of the “FibroScan-AST (FAST) Score For The ...

Please provide your email address to receive an email when new articles are posted on . Researchers recommended the FibroScan-AST score to target those at risk for MASH. The score should be used with ...

PARIS & WALTHAM, Mass.--(BUSINESS WIRE)--Echosens, a high-technology company offering the FibroScan family of products, today announces that distinguished researchers will present studies supporting ...

This article is brought to you by Our Lady of the Angels. An innovative non-invasive technology at Our Lady of the Angels is helping doctors better detect liver problems, leading to earlier treatment ...

MUSKEGON, Mich. -- It's known to many as the silent epidemic - a viral infection that spreads through blood contact and affects an estimated 3.5 million people nationwide. According to experts, half ...

This milestone opens a path for FibroScan ® to ultimately replace liver biopsy for patient enrollment and treatment response assessment in MASH drug development WESTBOROUGH, Mass., Sept. 8, 2025 ...

Experts say about one in 10 Americans have some form of liver disease like hepatitis, cirrhosis or cancer.Many of those patients would have to undergo a core needle biopsy procedure, which is invasive ...

Please provide your email address to receive an email when new articles are posted on . PHILADELPHIA — FibroScan screening for nonalcoholic fatty liver disease and nonalcoholic steatohepatitis could ...

Liver fibrosis happens when persistent inflammation of the liver causes excessive scar tissue to build up in the organ and nearby blood vessels. The presence of scar tissue can impair overall liver ...

WEBVTT WOMAN'S DOCTOR. MINDY: WHAT YOU'RE LOOKING AT IS A PROCEDURE CALLED A FIBROSCAN OF THE LIVER. IT'S NON-INVASIVE SIMILAR TO AN ULTRASOUND. IT MEASURES THE DEGREE OF SCARRING, OR FIBROSIS, ON THE ...

This guidance replaces NICE’s medtech innovation briefing on FibroScan for assessing liver fibrosis and cirrhosis in primary care (MIB216). Diagnostics guidance 48 has been migrated to HealthTech ...